Yu Wei, Shao Anwen, Ren Xiaoqiu, Chen Zexin, Xu Jinghong, Wei Qichun
Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
Department of Neurosurgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
Brain Sci. 2022 Feb 14;12(2):266. doi: 10.3390/brainsci12020266.
This study aims to investigate expression patterns in paired primary and recurrent gliomas. From January 2008 to December 2014, 42 patients who underwent surgical resections of primary and recurrent gliomas were retrospectively included. protein expression in tumors was evaluated through immunohistochemistry. In primary gliomas, and expression was evident in 9 (22.0%) and 14 (33.3%) patients. In the paired recurrent glioma, and expression was evident in 25 (61.0%) and 31 (74.0%) lesions. Both and showed significantly enhanced expression after recurrence ( < 0.005; < 0.005). For expression in recurrent gliomas, the adjuvant therapy group showed significantly increased expression compared to primary gliomas ( < 0.005). For - primary gliomas, if the matched recurrent gliomas showed +, the PFS became worse than the remaining recurrent gliomas - (12.7 vs. 25.9 months, = 0.032). Interestingly, for - primary gliomas, if the matched recurrent gliomas showed +, the OS became better than the remaining recurrent gliomas - (33.8 vs. 17.5 months, < 0.001). In the study, we found the expression of / increased significantly in recurrent gliomas and the elevated level of was tightly associated with adjuvant treatment, suggesting the potential therapeutic and predictive value of and in the treatment of recurrent gliomas.
本研究旨在调查原发性和复发性胶质瘤配对样本中的表达模式。2008年1月至2014年12月，对42例行原发性和复发性胶质瘤手术切除的患者进行回顾性纳入研究。通过免疫组织化学评估肿瘤中的蛋白质表达。在原发性胶质瘤中，9例（22.0%）患者有明显表达，14例（33.3%）患者有明显表达。在配对的复发性胶质瘤中，25例（61.0%）病灶有明显表达，31例（74.0%）病灶有明显表达。复发后和的表达均显著增强（<0.005；<0.005）。对于复发性胶质瘤中的表达，辅助治疗组与原发性胶质瘤相比表达显著增加（<0.005）。对于原发性胶质瘤，如果配对的复发性胶质瘤显示为+，则无进展生存期比其余复发性胶质瘤-更差（12.7个月对25.9个月，=0.032）。有趣的是，对于原发性胶质瘤，如果配对的复发性胶质瘤显示为+，则总生存期比其余复发性胶质瘤-更好（33.8个月对17.5个月，<0.001）。在本研究中，我们发现/在复发性胶质瘤中的表达显著增加，且水平升高与辅助治疗密切相关，提示和在复发性胶质瘤治疗中具有潜在的治疗和预测价值。
